SLC6A3 and multiple system atrophy: Further studies showed the reduction of DAT immunoreactivity in PBL also in subjects suffering MSA [86] (Table 3); in these patients, a slight, not significant, increase of DAT immunoreactivity in PBL was measured following withdrawal from L-DOPA therapy [86].